Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal.

Abstract

We provide a real-world overview of multiple myeloma (MM) treatment patterns, outcomes and healthcare resource use (HRU) in Portugal. Data were collected retrospectively from consecutive patients diagnosed/treated at the Portuguese Oncology Institute of Porto (IPO-Porto) between 2012 and 2015. Primary objectives were progression-free survival (PFS) and overall survival (OS), with treatment patterns and HRU secondary. Analysis was by line of therapy (LOT), and post hoc by age (<65/≥65years). 165, 73 and 32 patients received first, second and third LOTs respectively (N=187). OS probabilities were 91.5%, 83.2% (<65years) and 86.6%, 65.3% (≥65years) at 12, 24months respectively. PFS decreased from the start of each LOT for both age groups and was less for patients ≥65years. Younger patients received more combination treatment (immunomodulatory drugs+proteasome inhibitors) and stem cell transplants, and had higher mean costs than older patients (€81,213 vs. €36,864 where three LOTs were received). Cost drivers were medications, transplantations and hospitalisations. Our results suggest divergence between younger and older MM patients. Older patients had lower OS and PFS probabilities, HRU costs and fewer stem cell transplantations. The treatment patterns in each LOT may differ from other countries' findings, suggesting treatment heterogeneity.